Esophagectomy for clinical high-grade dysplasia

Rice, Thomas W.; Murthy, Sudish C.; Mason, David P.; Rybicki, Lisa A.; Yerian, Lisa M.; Dumot, John A.; Rodriguez, Cristina P.; Blackstone, Eugene H.
July 2011
European Journal of Cardio-Thoracic Surgery;Jul2011, Vol. 40 Issue 1, p113
Academic Journal
Abstract: Objective: Esophageal high-grade dysplasia/tumor in situ (HGD/Tis) management is in evolution. However, treatment decisions must be made on clinical staging, which may not reflect pathologic staging. Long-term randomized trial information, large treatment series, and cancer registry data do not exist to guide treatment decisions. This evaluation of esophagectomy for clinically diagnosed HGD (cHGD) serves as a reference point for future therapies. Methods: From a 1296-patient prospective esophagectomy database, 134 patients were diagnosed with cHGD (HGD without detectable mass at biopsy) before esophagectomy (mean age 60±10 years, 120 [90%] male, and 132 [99%] Caucasian). Median follow-up was 7.1 years. Results: Histopathologic cell type was adenocarcinoma in 124 (93%) patients. Pathologic T (tumor) classification (pT) was 77 (57%) pHGD, 46 (34%) pT1a, eight (6%) pT1b, and one each (1%) indefinite for dysplasia, low-grade dysplasia, and pT2. Three (2%) had regional lymph node metastases (pT1N1M0). There was one hospital death (0.7%) and four deaths from recurrent cancer. Survival at 1 month, 6 months, and 5, 10, and 15 years was 99%, 97%, 96%, 94%, 82%, and 75%, respectively. Survival was at least that of a matched population. Older age and poor lung function predicted worse survival. Sixteen patients developed nonesophageal cancers, 6.1 times greater than expected. Conclusions: Despite clinical staging errors, survival following esophagectomy for cHGD is excellent. The diagnosis of cHGD does not alter survival referenced to the matched general population; however, cHGD patients appear to be at increased risk of second nonesophageal primary cancers. Therapy for cHGD should be patient specific, because patient and not cancer characteristics determine survival.


Related Articles

  • A randomised controlled trial of ALA vs. Photofrin photodynamic therapy for high-grade dysplasia arising in Barrett's oesophagus. Dunn, J.; Mackenzie, G.; Banks, M.; Mosse, C.; Haidry, R.; Green, S.; Thorpe, S.; Rodriguez-Justo, M.; Winstanley, A.; Novelli, M.; Bown, S.; Lovat, L. // Lasers in Medical Science;May2013, Vol. 28 Issue 3, p707 

    Photofrin photodynamic therapy (PDT) is a licenced treatment for Barrett's oesophagus (BE) with high-grade dysplasia (HGD) but causes strictures and photosensitivity and complete reversal of dysplasia (CR-HGD) by 50 % at 5 years. 5-Aminolaevulinic acid (ALA) is an alternative treatment with...

  • Incidence and Predictors of Adenocarcinoma Following Endoscopic Ablation of Barrett's Esophagus. Yasuda, Kazuhiro; Choi, Sung; Nishioka, Norman; Rattner, David; Puricelli, William; Tramontano, Angela; Kitano, Seigo; Hur, Chin // Digestive Diseases & Sciences;Jul2014, Vol. 59 Issue 7, p1560 

    Background: The rate and risk factors of recurrent or metachronous adenocarcinoma following endoscopic ablation therapy in patients with Barrett's esophagus (BE) have not been specifically reported. Aim: The aim of this study was to determine the incidence and predictors of adenocarcinoma after...

  • Minimally invasive esophagectomy for Barrett's with high-grade dysplasia and early adenocarcinoma of the esophagus. Pennathur, Arjun; Awais, Omar; Luketich, James D. // Journal of Gastrointestinal Surgery;Jun2010, Vol. 14 Issue 6, p948 

    The article explores some aspects of applying minimally invasive esophagectomy for Barrett's with high grade dysplasia (HGD) and early adenocarcinoma of the esophagus. HGD refers to intraepithelial neoplasia that has not entered the basement membrane. Studies show that the incidence of occult...

  • Long-term Follow-up After Anti-reflux Surgery in Patients with Barrett's Esophagus. Zehetner, Joerg; DeMeester, Steven R.; Ayazi, Shahin; Costales, Jesse L.; Augustin, Florian; Oezcelik, Arzu; Lipham, John C.; Sohn, Helen J.; Hagen, Jeffrey A.; DeMeester, Tom R. // Journal of Gastrointestinal Surgery;Oct2010, Vol. 14 Issue 10, p1483 

    Background: Factors associated with the risk of progression of Barrett's esophagus remain unclear, and the impact of therapy on this risk remains uncertain. The aim of this study was to assess patients followed long-term after anti-reflux surgery for Barrett's esophagus. Methods: A retrospective...

  • Editorial: Endpoints for Radiofrequency Ablation in Barrett's Dysplasia. Gorospe, Emmanuel C; Sun, Gang; Wang, Kenneth K // American Journal of Gastroenterology;Feb2013, Vol. 108 Issue 2, p197 

    The need to combat the rising incidence of esophageal adenocarcinoma with its dismal prognosis has led to increasing development of many endoscopic treatments for Barrett's esophagus (BE). Radiofrequency ablation (RFA) has been shown to be a safe and effective endoscopic treatment modality for...

  • Polypoid Dysplasia in Barrett’s Esophagus: Diagnosis, Management, and Very Different Outcomes in Two Consecutive Cases. Murphy, Megan; Tofani, Christina; Gandhi, Kunjal; Infantolino, Anthony // Case Reports in Gastrointestinal Medicine;11/23/2016, p1 

    Background. Barrett’s esophagus is associated with an increased risk of adenocarcinoma. Dysplasia in Barrett’s esophagus is a precursor to adenocarcinoma. Rarely, dysplastic polypoid lesions are superimposed on Barrett’s esophagus. Most reported cases of polypoid dysplasia...

  • Case Report: Mesenchymal Chondrosarcoma of the Lumbar Spine in a Child. Zibis, Aristidis; Wade Shrader, M.; Segal, Lee // Clinical Orthopaedics & Related Research;Aug2010, Vol. 468 Issue 8, p2288 

    Chondrosarcomas of the spine constitute 4% to 10% of all primary spinal bone tumors and approximately 70% of the cases occur during the second or third decade of life. Mesenchymal chondrosarcoma is a rare aggressive variant of chondrosarcoma. The prognosis of mesenchymal chondrosarcoma is...

  • The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis. Desai, Tusar K.; Krishnan, Kumar; Samala, Niharika; Singh, Jashanpreet; Cluley, John; Perla, Subaiah; Howden, Colin W. // Gut;Jul2012, Vol. 61 Issue 7, p970 

    Introduction: The risk of oesophageal adenocarcinoma (OAC) in non-dysplastic Barrett's oesophagus (BO) may have been overestimated. The objective was to estimate the incidence of OAC in patients with BO without dysplasia. Methods:The authors searched MEDLINE and EMBASE from 1966 to 2011 and...

  • HPV Vaccine Protein L1 Predicts Disease Outcome of High-Risk HPV+ Early Squamous Dysplastic Lesions. Henrik Griesser // American Journal of Clinical Pathology;Dec2009, Vol. 132 Issue 6, p840 

    Prediction of the clinical outcome of nonadvanced, early dysplastic lesions is one of the unresolved problems of cervical cancer screening programs. We examined the influence of human papillomavirus (HPV) L1 capsid protein detection in a randomized, prospective study of 187 high-risk HPV+ early...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics